Vall d’Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): A new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)
2018; Elsevier BV; Volume: 29; Linguagem: Inglês
10.1093/annonc/mdy269.090
ISSN1569-8041
AutoresCinta Hierro, Ignacio Matos, Juan Martín-Liberal, Mora Amat, Eudald Felip, Marinha Costa Rivas, María Vieito, Irene Braña, A. Ázaro, M.C. Perez-Gago, Alena Gros, Joan Carles, Ana Oaknin, Teresa Macarulla, Cristina Saura, Núria Pardo, Eva Muñoz‐Couselo, Josep Tabernero, Rodrigo Dienstmann, Elena Garralda,
Tópico(s)Radiomics and Machine Learning in Medical Imaging
ResumoBackground: The Royal Marsden Hospital score (RMHs) (albumin upper limit of normal [ULN], and >two sites of metastases [met]) is a validated prognostic index for Ph1pt selection. Recently, a lung immune prognostic index (LIPI) (derived neutrophil/(leukocytes minus neutrophils) ratio [dNLR]>3, and LDH>ULN) proved to be useful for identifying pts with different outcomes under ICI. We aimed to improve pt selection for ICI Ph1 trials by developing a composite VIO that included all clinical-laboratory (CL) variables linked with worse median Overall Survival (mOS).
Referência(s)